TARRYTOWN, N.Y. — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have progressed after at least three prior therapies. Linvoseltamab is an investigational bispecific...
Latest News
FOOTBALL– The Leyden Lions suffered what could be looked at as a devastating 34-10 preseason loss at home to the Racine Raiders on Saturday, but the plight of a little 12-year-old girl puts back into perspective what’s really important to the players, coaches and the community. And thoughts about the...
BASKING RIDGE, N.J. — Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma patient treated with LSTA1 in combination...
BASKING RIDGE, N.J.— Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to LSTA1, the Company’s lead product candidate,...
BASKING RIDGE, N.J. — Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (“GBM”). The trial is...
BASKING RIDGE, N.J. — Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LSTA1, the Company’s lead product candidate,...
WASHINGTON, DC – Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances. The study is the first of its kind to incorporate healthcare...
Padma Panniker considers herself lucky. Although she suffers from blurry vision and chronic pain, she can still move, and even drives herself around; something unusual when compared with many multiple sclerosis (MS) sufferers. “Some of them are wheelchair-bound and even lose the ability to speak because of the illness,” she...
LncRNA DLGAP1-AS2 is overexpressed in patients with non-small cell lung cancer (NSCLC) and may promote cell proliferation by upregulating cyclin D1 by sponging miR-503, according to a study published in BMC Pulmonary Medicine. Effective targets for lung cancer remain lacking. However, it has been suggested that lncRNAs and miRNAs are promising...
Taking care of a newborn is no easy feat. From feeding to changing, a baby requires all of one’s attention. Now imagine if the feeding and changing were the easy part. What if when you touched your baby ever-so-slightly, you risked damaging him or her for life? That is precisely...